Ranbaxy Cleared To Launch Diovan Generic In U.S. With Exclusivity
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories is free to launch its generic version of the Novartis drug Diovan (valsartan) for treating high blood pressure in the U.S. after gaining U.S. FDA approval.
You may also be interested in...
Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit
A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.